This is a working overview of TH9507, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
It has been argued that happiness at work is one of the driving forces behind positive outcomes at work, rather than just being a resultant product. Despite a large body of positive psychological research into the relationship between happiness and productivity, happiness at work has traditionally been seen as a potential by-product of positive outcomes at work, rather than a pathway to success in business. However a growing number of scholars, including Boehm and Lyubomirsky, argue that it should be viewed as one of the major sources of positive outcomes in the workplace.
=== Hemolytic crisis === A hemolytic crisis, or hyperhemolytic crisis, is characterized by an accelerated rate of red blood cell destruction leading to anemia, jaundice, and reticulocytosis. Hemolytic crises are a major concern with sickle-cell disease and G6PD deficiency.
January 24 Trump threatens Canada with 100% tariffs on all goods if the country's prime minister Mark Carney strikes a trade deal with China. Killing of Alex Pretti: A 37-year-old man is shot and killed by United States Immigration and Customs Enforcement agents in Minneapolis, Minnesota. One person is killed and 14 others are injured in a gas explosion and multiple-alarm fire at a 17-story apartment building in the Bronx, New York City. January 25 Over a million people are without power across the South and at least 10,000 flights are canceled due to the winter storm. Six people are killed when a Bombardier Challenger 650 aircraft crashes at Bangor International Airport in Maine. January 27 – Representative Ilhan Omar is attacked during a town hall meeting in Minneapolis when an audience member sprays a chemical substance at her. A 55-year-old man is arrested and charged with third-degree assault, while Omar herself is uninjured. January 28 FBI investigation into the 2020 United States presidential election in Georgia: The Federal Bureau of Investigation raids the election center in Fulton County, Georgia. Amazon announces 16,000 job layoffs in its second round of corporate reduction. January 29 – Journalist and former CNN host Don Lemon is arrested by federal authorities after he reported on a protest inside a church in St. Paul, Minnesota earlier in the month. January 30 Three million pages related to the Epstein Files, including 2,000 videos and 180,000 images, are released to the public, implicating many high-profile public figures worldwide.
=== Miscellaneous uses === Argon is used for thermal insulation in energy-efficient windows. Argon is also used in technical scuba diving to inflate a dry suit because it is inert and has low thermal conductivity. Argon is used as a propellant in the development of the Variable Specific Impulse Magnetoplasma Rocket (VASIMR). Compressed argon gas is allowed to expand, to cool the seeker heads of some versions of the AIM-9 Sidewinder missile and other missiles that use cooled thermal seeker heads. The gas is stored at high pressure. Argon-39, with a half-life of 269 years, has been used for a number of applications, primarily ice core and ground water dating. Also, potassium–argon dating and related argon-argon dating are used to date sedimentary, metamorphic, and igneous rocks. Argon has been used by athletes as a doping agent to simulate hypoxic conditions. In 2014, the World Anti-Doping Agency (WADA) added argon and xenon to the list of prohibited substances and methods, although at this time there is no reliable test for abuse.
Sources: en.wikipedia.org
=== Cardiovascular system === Nicotine exerts several significant effects on the cardiovascular system. Primarily, it stimulates the sympathetic nervous system, leading to the release of catecholamines. This activation results in an increase in heart rate and blood pressure, as well as enhanced myocardial contractility, which raises the workload on the heart. Additionally, nicotine causes systemic vasoconstriction, including constriction of coronary arteries, which can reduce blood flow to the heart. Long-term exposure to nicotine may impair endothelial function, potentially contributing to atherosclerosis. Furthermore, nicotine has been associated with the development of cardiac arrhythmias, particularly in individuals who already have underlying heart disease. The effects of nicotine can be differentiated between short-term and long-term use. Short-term nicotine use, such as that associated with nicotine replacement therapy (NRT) for smoking cessation, appears to pose little cardiovascular risk, even for patients with known cardiovascular conditions. In contrast, longer-term nicotine use may not accelerate atherosclerosis but could contribute to acute cardiovascular events in those with pre-existing cardiovascular disease. Many severe cardiovascular effects traditionally associated with smoking may not be solely attributable to nicotine itself. Cigarette smoke contains numerous other potentially cardiotoxic substances, including carbon monoxide and oxidant gases.
== History == In the early 1940s clinicians used extracts of growth factors and cytokines for healing. The term 'platelet-rich plasma' was first used in 1954 by Kingsley and in the 1960s the first PRP blood banks were established, becoming popular by the 1970s. In the 1970s PRP was used in hematology, originally for transfusions to treat thrombocytopenia. Ten years later it was used for maxillofacial surgeries. PRP was first used in Italy in 1987 in an open heart surgery procedure. In 2006 PRP was starting to be considered of potential use for both androgenic alopecia and alopecia areata.
Mechanical or elastic gauges depend on a Bourdon tube, diaphragm, or capsule, usually made of metal, which will change shape in response to the pressure of the region in question. A variation on this idea is the capacitance manometer, in which the diaphragm makes up a part of a capacitor. A change in pressure leads to the flexure of the diaphragm, which results in a change in capacitance. These gauges are effective from 103 torr to 10−4 torr, and beyond. Thermal conductivity gauges rely on the fact that the ability of a gas to conduct heat decreases with pressure. In this type of gauge, a wire filament is heated by running current through it. A thermocouple or Resistance Temperature Detector (RTD) can then be used to measure the temperature of the filament. This temperature is dependent on the rate at which the filament loses heat to the surrounding gas, and therefore on the thermal conductivity. A common variant is the Pirani gauge which uses a single platinum filament as both the heated element and RTD. These gauges are accurate from 10 torr to 10−3 torr, but they are sensitive to the chemical composition of the gases being measured. Ionization gauges are used in ultrahigh vacuum. They come in two types: hot cathode and cold cathode. In the hot cathode version an electrically heated filament produces an electron beam. The electrons travel through the gauge and ionize gas molecules around them. The resulting ions are collected at a negative electrode. The current depends on the number of ions, which depends on the pressure in the gauge.
In 1958 Pius XII approved of the image in association with the devotion to the Holy Face of Jesus, and decreed that the "Feast of the Holy Winding Sheet of Christ" be celebrated every year on Shrove Tuesday. In 1936 Pius XII had referred to the Shroud as a "holy thing perhaps like nothing else". In 1998 Pope John Paul II called the Shroud a "distinguished relic" and "a mirror of the Gospel". His successor, Pope Benedict XVI, called it an "icon written with the blood of a whipped man, crowned with thorns, crucified and pierced on his right side". In 2013 Pope Francis referred to it as an "icon of a man scourged and crucified". In 1983, archbishops of the Catholic Church and Greek Orthodox Church, as well as clergy of several Protestant churches attended a prayer service at the Shroud exhibit in Turin, where they "offered their corporate blessing" to the exhibit. In 1983 the Shroud was given to the Holy See by the House of Savoy. However, as with all relics of this kind, the Roman Catholic Church made no pronouncements on its authenticity. As with other approved Catholic devotions, the matter has been left to the personal decision of the faithful, as long as the Church does not issue a future notification to the contrary. In the Church's view, whether the cloth is authentic or not has no bearing whatsoever on the validity of what Jesus taught or on the saving power of his death and resurrection. Pope John Paul II stated in 1998 that: "Since it is not a matter of faith, the Church has no specific competence to pronounce on these questions.
Elderly people – due to impaired intestinal absorption – and children, premenopausal women, and pregnant women whose diets are low in animal foods are all at increased risk. Deficiency is especially harmful in pregnancy, childhood, and older adults. It can lead to neuropathy, megaloblastic anemia, and pernicious anemia, causing symptoms including fatigue, paresthesia, depression, cognitive decline, ataxia, and even irreversible nerve damage. In infants, untreated deficiency may result in neurological impairment and anemia. Maternal deficiency increases the risk of miscarriage, neural tube defects, and delayed development in offspring. Folate levels may modify the presentation of symptoms and disease course.
Sources: en.wikipedia.org
Tunable metamaterials allow arbitrary adjustments to frequency changes in the refractive index. A tunable metamaterial expands beyond the bandwidth limitations in left-handed materials by constructing various types of metamaterials.
=== Anaerobic exercise protein needs === Research also indicates that individuals performing strength training activity require more protein than sedentary individuals. Strength-training athletes may increase their daily protein intake to a maximum of 1.4–1.8 g per kg body weight to enhance muscle protein synthesis, or to make up for the loss of amino acid oxidation during exercise. Many athletes maintain a high-protein diet as part of their training. In fact, some athletes who specialize in anaerobic sports (e.g., weightlifting) believe a very high level of protein intake is necessary, and so consume high protein meals and also protein supplements.
Later, during the 1990s, Heseltine committed a minor gaffe when he joked in a speech about how he had strung creditors along. Between 1960 and 1964, Heseltine also worked as a part-time interviewer for ITV, very likely, in Crick's view, to maintain his public profile as an aspiring politician.
Pea protein is rich in nutrients such as protein and carbohydrates. Pea protein also contains vitamins and minerals and is low in fat. While generally rich in protein, the actual protein content of peas is variable and influenced by both genetic factors and environmental factors (such as soil and climate in which the peas are cultivated). Typically, peas contain 23.1–30.9% protein, 1.5–2.0% fat, and minor constituents such as vitamins, phytic acid, saponins, polyphenols, minerals, and oxalates. They also contain several classes of protein: globulin, albumin, prolamin, and glutelin. The proteins are mainly albumins and globulins, which account for 10-20% and 70-80% of the protein in the pea seed, respectively. The albumins are water-soluble and considered the metabolic and enzymatic proteins, while the globulins are salt soluble and act as the storage proteins for the seed. Globulins can be further classified into legumin and vicilin, which belong to the 11S and 7S seed storage protein classes, respectively. Legumin is a hexameric protein, and vicilin proteins are trimers. Pea protein is considered to be a complete protein, containing all the essential amino acids. However, it is not balanced, as it has high levels of lysine and threonine but relatively low amounts of sulfur-containing amino acids including cysteine and methionine. Pea seeds contain 60-65% carbohydrates mainly composed of oligosaccharides, monosaccharides, polysaccharides, and disaccharides. The major carbohydrate fraction in peas is starch, which is the major storage carbohydrate in the cotyledons.
In September 2020, an in vitro and in vivo study found that DMT present in the ayahuasca infusion promotes neurogenesis. DMT has been found to be a psychoplastogen, a compound capable of promoting rapid and sustained neuroplasticity that may have wide-ranging therapeutic benefit. The cryo-EM structures of the serotonin 5-HT2A receptor with DMT, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.